SCHEMBL20549671

SCHEMBL20549671

CCc1cnn2c(NC3CCCC(N)C3)nc(N[C@H]3CC[C@H](N(C)C)CC3)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A1 P68400 4/20 0.46
▸ CDK9 P50750 10/20 0.37
▸ CCNT1 O60563 9/20 0.37
▸ CDK1 P06493 3/20 0.37
▸ EGFR P00533 1/20 0.37
▸ PRKCA P17252 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ CDK2 P24941 6/20 0.36
▸ CCNA2 P20248 4/20 0.36
▸ CCNE1 P24864 3/20 0.36
▸ CCNA1 P78396 3/20 0.36
▸ CCNE2 O96020 1/20 0.36
▸ CDK7 P50613 4/20 0.35
▸ CDK5 Q00535 3/20 0.35
▸ CDK5R1 Q15078 3/20 0.35
▸ CCNH P51946 3/20 0.35
▸ CDK4 P11802 2/20 0.35
▸ CCND1 P24385 2/20 0.35
▸ CDK3 Q00526 2/20 0.35
▸ CDK6 Q00534 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18122197 1.00 CSNK2A1 (0.46) CSNK2A1CDK9CCNT1CDK1EGFR
SCHEMBL21473010 0.86 CSNK2A1 (0.52) CSNK2A1CDK9CDK2CCNA2CCNE1
SCHEMBL25736235 0.85 CSNK2A1 (0.45) CSNK2A1CDK9IRAK4CDK2CDK7
SCHEMBL25737109 0.85 CSNK2A1 (0.47) CSNK2A1CDK9CDK2CCNA2CCNE1
SCHEMBL20549636 0.83 CSNK2A1 (0.46) CSNK2A1CDK9CCNT1CDK2CCNE1
SCHEMBL20550115 0.83 CSNK2A1 (0.46) CSNK2A1CDK9IRAK4CDK2CDK7
SCHEMBL20550117 0.83 CSNK2A1 (0.46) CSNK2A1CDK9IRAK4CDK2CDK7
SCHEMBL18122196 0.82 CSNK2A1 (0.44) CSNK2A1CDK9TTK
SCHEMBL25736291 0.82 CSNK2A1 (0.44) CSNK2A1CDK9TTK
SCHEMBL18122682 0.78 CSNK2A1 (0.39) CSNK2A1CDK9CCNT1CDK1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50776-E1 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-02-03 — — US disclosed
US-12098154-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-09-24 — — US disclosed
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-15 — — US disclosed
EP-3273966-B1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA FARBER CANCER INST INC (US) 2023-05-03 — — EP disclosed
US-20220242865-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-08-04 — — US disclosed
US-11325910-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-10 — — US disclosed
CN-107427521-B Inhibitors of cyclin dependent kinases 达纳-法伯癌症研究所股份有限公司 2021-08-03 — — CN disclosed
US-20200277292-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-03 — — US disclosed
US-10550121-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-02-04 — — US disclosed
US-20190315747-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-17 — — US disclosed
US-20180319801-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325910-B2 Inhibitors of cyclin-dependent kinases CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885
US-20220242865-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885
US-20200277292-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885
US-10550121-B2 Inhibitors of cyclin-dependent kinases CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885
US-20180319801-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885
US-12098154-B2 Inhibitors of cyclin-dependent kinases CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885
US-20190315747-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885
US-20230183240-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK3, CDK13, CDK1 CSNK2A1 403/4885CDK9 21/4885CCNT1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback